The effect of lipoic acid and vitamin E therapies in individuals with the metabolic syndrome

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 6, 2013, Pages 543-549

  Manning, P J ^a   Sutherland, W H F ^a   Williams, S M ^a   Walker, R J ^a   Berry, E A ^a   De Jong, S A ^a   Ryalls, A R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Antioxidant; Lipoic acid; Metabolic syndrome; Non esterified fatty acids; Vitamin E

Indexed keywords

ADIPONECTIN; ALPHA TOCOPHEROL; ANTIOXIDANT; FATTY ACID; INSULIN; THIOCTIC ACID;

ADULT; AGED; ARTICLE; BLOOD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INTERVENTION STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADIPONECTIN; ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BLOOD GLUCOSE; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERVENTION STUDIES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; THIOCTIC ACID; VITAMIN E;

EID: 84878932093     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2011.11.006     Document Type: Article

References (32)

1. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
2. Festa A., D'Agostino R., Howard G., Mykkanen L., Tracy R.P., Haffner S.M. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42-47.
3. Meigs J.B., Larson M.G., Fox C.S., Keaney J.F., Vasan R.S., Benjamin E.J. Association of oxidative stress, insulin resistance, and diabetes risk phenotypes: the Framingham offspring study. Diabetes Care 2007, 30:2529-2535.
4. Laws A., Hoen H.M., Selby J.V., Saad M.F., Haffner S.M., Howard B.V., et al. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arterioscler Thromb Vasc Biol 1997, 17:64-71. for the Insulin Resistance Atherosclerosis Study (IRAS) Investigators.
5. Matsuzawa Y., Funahashi T., Kihara S., Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol 2004, 24:29-33.
6. Ford E.S. Risk for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005, 28:1769-1778.
7. Packer L., Kraemer K., Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 2001, 17:888-895.
8. Shay K., Moreau R., Smith E., Smith A., Hagen T. Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential. Biochim Biophys Acta 2009, 1790:1149-1160.
9. Monette J., Gomez L., Moreau R., Dunn K., Butler J., Finlay L., et al. (R)-alpha-Lipoic acid treatment restores ceramide balance in aging rat cardiac mitochondria. Pharmacol Res 2011, 63:23-29.
10. Jacob S., Ruus P., Hermann R., Tritschler H., Maerker E., Renn W., et al. Oral administration of RAC-α-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999, 3/4:309-314.
11. Jacob S., Streeper R.S., Fogt D.L., Hokama J., Tritschler H., Dietze G., et al. The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle. Diabetes 1996, 45:1024-1029.
12. Streeper R.S., Henriksen E.J., Jacob S., Hokama J.Y., Fogt D.L., Tritschler H.J. Differential effects of lipoic acid stereoisomers on glucose metabolism in insulin-resistant skeletal muscle. Am J Physiol 1997, 273:E185-E191.
13. Huong D.T., Ide T. Dietary lipoic acid-dependent changes in the activity and mRNA levels of hepatic lipogenic enzymes in rats. Br J Nutr 2008, 100:79-87.
14. Sola S., Mir M.Q.S., Cheema F.A., Khan-Merchant N., Menon R., Parthasarathy S., et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation 2005, 111:343-348.
15. Ziegler D., Low P., Litchy W., Boulton A., Vinik A., Freeman R., et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011, 34:2054-2060.
16. Gonzalez-Perez O., Gonzalez-Castaneda R.E. Therapeutic perspectives on the combination of α-lipoic acid and vitamin E. Nutr Res 2006, 26:1-5.
17. Haramaki N., Packer L., Assandnazari H., Zimmer G. Cardiac recovery during post-ischemic reperfusion is improved by combination of vitamin E with dihydrolipoic acid. Biochem Biophys Res Commun 1993, 196:1101-1107.
18. Paolisso G., D'Amore A., Giugliano D., Ceriello A., Varricchio M. D'Onofrio. Pharmacological doses of vitamin E improve insulin action in healthy subjects and non-insulin dependent diabetic patients. Am J Clin Nutr 1993, 57:650-656.
19. Manning P.J., Sutherland W.H., Walker R.J., Williams S.M., De Jong S.A., Ryalls A.R., et al. Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects. Diabetes Care 2004, 9:2166-2171.
20. Devaraj S., Jialal I. Low-density lipoprotein postsecretoery modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol. Circulation 2000, 102:191-196.
21. Upritchard J.E., Sutherland W.H.F., Mann J.I. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 2000, 23:733-738.
22. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R., Appel L., Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142:37-46.
23. de Oliveira A.M., Carvalho Rondó P.H., Luzia L.A., D'Abronzo F.H., Illison V.K. The effects of lipoic acid and α-tocopherol supplementation on the lipid profile and insulin sensitivity of patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Diab Res Clin Pract 2011, 92:253-260.
24. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
25. Self W.T., Tsai L., Stadtman T.C. Synthesis and characterization of selenotrisulfide-derivatives of lipoic acid and lipoamide. Proc Natl Acad Sci U S A 2000, 97:12481-12486.
26. Thurnham D.I., Smith E., Flora P.S. Concurrent liquid-chromatographic assay of retinol, alpha-tocopherol, beta-carotene, alpha-carotene, lycopene, and beta-cryptoxanthin in plasma, with tocopherol acetate as internal standard. Clin Chem 1988, 34:377-381.
27. Wallace T., Levy J., Matthews D. Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
28. De Fronzo Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010, 53:1270-1287.
29. Belfort R., Mandarino L., Kashyap S., Wirfel K., Pratipanawatr T., Berria R., et al. Dose-response effect of elevated plasma free fatty acid on insulin signalling. Diabetes 2005, 54:1640-1648.
30. Bajaj M., Suraamornkul S., Kahyap S., Cusi K., Mandarino L., DeFronzo R.A. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab 2004, 89:4649-4655.
31. Butler J., Hagen T., Moreau R. Lipoic acid improves hypertriglyceridemia by stimulating triacylglycerol clearance and downregulating liver triacylglycerol secretion. Arch Biochem Biophys 2009, 485:63-71.
32. Teichert J., Kern J., Tritschler H.J., Ulrich H., Preiss R. Investigations on the pharmacokinetics of alpha-lipoic acid in healthy volunteers. Int J Clin Pharmacol Ther 1998, 36:625-628.